This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Srinivasan, S. K. Articles by Cooper, L. T. Search for Related Content PubMed PubMed Citation Articles by Srinivasan, S. K. Articles by Cooper, L. T., JR Social Bookmarking                         What's this?

Recombinant Tissue Plasminogen Activator for the Treatment of Cutaneous Infarctions in Antiphospholipid Antibody Syndrome

A Case Report

Mark R. Pittelkow, MD

Leslie T. Cooper, JR, MD

Antiphospholipid antibody syndrome (APAS) commonly presents with cutaneous infarctions mimicking thromboembolic vaso-occlusive disease. Systemic anticoagulation is the standard of care for this disorder, but treatment failures can occur. The authors report the first successful treatment of cutaneous infarctions due to APAS with low-dose, intravenous tissue plas minogen activator (rTPA) in a patient who failed to improve with high-dose anticoagulation. Wound healing was associated with a marked improvement in blood flow as assessed by scanning laser Doppler. The authors recommend that patients presenting with cutaneous infarctions in the absence of atherosclerosis be evaluated for APAS, and that fibrinolytic therapy be considered if cutaneous infarction persists despite anticoagulant therapy.

Angiology, Vol. 52, No. 9, 635-639 (2001)
DOI: 10.1177/000331970105200908


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?